Pharma BD Deal Intelligence
AstraZeneca acquired TeneoTwo for $1.3B for blood cancer drug portfolio.
SOUNDTRACK-F1 (NCT06549595): Phase 3, surovatamig (AZD0486) + rituximab vs chemoimmunotherapy in previously untreated follicular lymphoma; Recruiting.
AstraZeneca to acquire TeneoTwo in deal worth up to $1.26 billion to strengthen haematological cancer pipeline with bispecific T-cell engager.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca acquired US biotech TeneoTwo (a TeneoBio spinout) to add its single clinical-stage asset, TNB-486 — a fully human CD19xCD3 bispecific T-cell engager for B-cell hematologic malignancies. The deal was structured as $100M upfront plus up to $805M in R&D milestones and up to $360M in commercial milestones (up to ~$1.27B total). Announced January 2022 and completed August 2022. Since the deal, AstraZeneca renamed the asset AZD0486 (INN surovatamig) and advanced it from Phase 1 to Phase 3: at ASH 2024, doses ≥2.4 mg produced a 96% overall response and 85% complete response with rapid MRD clearance in relapsed/refractory follicular lymphoma, with CRS in 45% of patients but all Grade 1. The pivotal Phase 3 SOUNDTRACK-F1 trial (NCT06549595) now tests surovatamig plus rituximab versus chemoimmunotherapy in previously untreated follicular lymphoma, with Phase 2 SOUNDTRACK-B running in relapsed/refractory NHL — validating the original bispecific T-cell-engager thesis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / TeneoTwo Inc. (this deal) | 2022 | $1.3B | 54 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Oncology deals